We mined the literature for proteomics data to examine the occurrence and metastasis of prostate cancer (PCa) through a bioinformatics analysis. We divided the differentially expressed proteins (DEPs) into two groups: the group consisting of PCa and benign tissues (P&b) and the group presenting both high and low PCa metastatic tendencies (H&L). In the P&b group, we found 320 DEPs, 20 of which were reported more than three times, and DES was the most commonly reported. Among these DEPs, the expression levels of FGG, GSN, SERPINC1, TPM1, and TUBB4B have not yet been correlated with PCa. In the H&L group, we identified 353 DEPs, 13 of which were reported more than three times. Among these DEPs, MDH2 and MYH9 have not yet been correlated with PCa metastasis. We further confirmed that DES was differentially expressed between 30 cancer and 30 benign tissues. In addition, DEPs associated with protein transport, regulation of actin cytoskeleton, and the extracellular matrix (ECM)–receptor interaction pathway were prevalent in the H&L group and have not yet been studied in detail in this context. Proteins related to homeostasis, the wound-healing response, focal adhesions, and the complement and coagulation pathways were overrepresented in both groups. Our findings suggest that the repeatedly reported DEPs in the two groups may function as potential biomarkers for detecting PCa and predicting its aggressiveness. Furthermore, the implicated biological processes and signaling pathways may help elucidate the molecular mechanisms of PCa carcinogenesis and metastasis and provide new targets for clinical treatment.

High magnetic field homogeneity is critical for magnetic resonance imaging (MRI), functional MRI, and MR spectroscopy (MRS) applications. B₀ inhomogeneity during MR scans is a long-standing problem resulting from magnet imperfections and site conditions, with the main issue being the inhomogeneity across the human body caused by differences in magnetic susceptibilities between tissues, resulting in signal loss, image distortion, and poor spectral resolution. Through a combination of passive and active shim techniques, as well as technological advances employing multi-coil techniques, optimal coil design, motion tracking, and real-time modifications, improved field homogeneity and image quality have been achieved in MRI/MRS. The integration of RF and shim coils brings a high shim efficiency due to the proximity of subjects. This technique will potentially be applied to high-density RF coils with a high-density shim array for improved B₀ homogeneity. Simultaneous shimming and image encoding can be achieved using multi-coil array, which also enables the development of novel encoding methods using advanced magnetic field control. Field monitoring enables the capture and real-time compensation for dynamic field perturbance beyond the static background inhomogeneity. These advancements have the potential to better use the scanner performance to enhance diagnostic capabilities and broaden applications of MRI/MRS in a variety of clinical and research settings. The purpose of this paper is to provide an overview of the latest advances in B₀ magnetic field shimming and magnetic field control techniques as well as MR hardware, emphasize their significance and potential impact on improving the data quality of MRI/MRS.

Free-running cardiac quantitative susceptibility mapping allows for accurate detection and quantification of intramyocardial hemorrhage in the setting of acute myocardial infarction.

Bladder cancer is the ninth most common cancer in the world; fewer than 15% of transitional-cell carcinoma patients survive 2 years if left untreated. Although radical cystectomy is the standard treatment of choice, much of them relapse and the necessity of adjuvant chemotherapy is still under debate. The aim of the study was to evaluate the efficacy of adjuvant intraarterial chemotherapy (IAC) with gemcitabine and cisplatin (GC) on locally advanced bladder cancer. This is a retrospective study on 60 patients with locally advanced bladder carcinoma who underwent radical cystectomy between May 2000 and June 2011. Patients were studied in two groups based on IAC and followed up for up to 5 years. Among 60 patients, there were 25 patients who underwent IAC (GC) after radical cystectomy (the IAC group) and 35 patients who underwent radical cystectomy alone (the control group). Although not significant, the relapse rates were slightly reduced in the IAC group than in the control group. Patients with IAC had a reduction in mortality compared with patients without IAC over 5 years. Specifically, IAC significantly reduced about 82% of mortality within the first year (hazard ratio = 0.18, 95% CI 0.03-0.97, P = 0.04). Additionally, IAC was well tolerated and safe. The most common adverse effect was transient myelosuppression (10/25, 40%), which was resolved by various medical treatments. Compared with radical cystectomy alone, radical cystectomy in combination with adjuvant IAC moderately but significantly reduces 1-year mortality. Our preliminary data showed only marginal benefit for the early survival. However, a randomized clinical study is needed to determine the long-term survival benefit.